Abstract
Persistent viral eradication or suppression through a defined course of Pegylated-interferon (PegIFN) or the administration of a long-term potent nucleot(s)ide analogues (NUCs) can impact positively the natural course of HBV infection by preventing disease progression. Despite the higher rates of off-therapy response achieved with PegIFN compared with NUC, its benefits are restricted to a subgroup of patients only. To increase the rates of patients who may benefit from PegIFN treatment, minimizing the adverse events, careful patient selections based on baseline features and on treatment HBsAg kinetics for individual treatment optimization are required.
| Original language | English |
|---|---|
| Pages (from-to) | 425-443 |
| Number of pages | 19 |
| Journal | Clinics in Liver Disease |
| Volume | 17 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Aug 2013 |
Fingerprint
Keywords
- Chronic hepatitis B
- HBsAg levels
- HBV DNA
- IL28B polymorphism
- Pegylated interferon
- Sustained response
ASJC Scopus subject areas
- Hepatology
Cite this
Results of treatment of chronic hepatitis B with pegylated interferon. / Viganò, Mauro; Mangia, Giampaolo; Lampertico, Pietro.
In: Clinics in Liver Disease, Vol. 17, No. 3, 08.2013, p. 425-443.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Results of treatment of chronic hepatitis B with pegylated interferon
AU - Viganò, Mauro
AU - Mangia, Giampaolo
AU - Lampertico, Pietro
PY - 2013/8
Y1 - 2013/8
N2 - Persistent viral eradication or suppression through a defined course of Pegylated-interferon (PegIFN) or the administration of a long-term potent nucleot(s)ide analogues (NUCs) can impact positively the natural course of HBV infection by preventing disease progression. Despite the higher rates of off-therapy response achieved with PegIFN compared with NUC, its benefits are restricted to a subgroup of patients only. To increase the rates of patients who may benefit from PegIFN treatment, minimizing the adverse events, careful patient selections based on baseline features and on treatment HBsAg kinetics for individual treatment optimization are required.
AB - Persistent viral eradication or suppression through a defined course of Pegylated-interferon (PegIFN) or the administration of a long-term potent nucleot(s)ide analogues (NUCs) can impact positively the natural course of HBV infection by preventing disease progression. Despite the higher rates of off-therapy response achieved with PegIFN compared with NUC, its benefits are restricted to a subgroup of patients only. To increase the rates of patients who may benefit from PegIFN treatment, minimizing the adverse events, careful patient selections based on baseline features and on treatment HBsAg kinetics for individual treatment optimization are required.
KW - Chronic hepatitis B
KW - HBsAg levels
KW - HBV DNA
KW - IL28B polymorphism
KW - Pegylated interferon
KW - Sustained response
UR - http://www.scopus.com/inward/record.url?scp=84881025752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881025752&partnerID=8YFLogxK
U2 - 10.1016/j.cld.2013.05.004
DO - 10.1016/j.cld.2013.05.004
M3 - Article
C2 - 23905814
AN - SCOPUS:84881025752
VL - 17
SP - 425
EP - 443
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
SN - 1089-3261
IS - 3
ER -